This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content
About ATTR-CMAbout

Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM

About ATTR-CMWhat is ATTR-CM?The different types of ATTR-CM

Menu

Close

DiagnosisDiagnosis

Example of description text sitting alongside header

Diagnosis of ATTR-CMSigns and symptomsClinical cluesFormal diagnosisEmerging treatmentsEducational resourcesEducational resources

Explore a range of educational resources to support the diagnosis of ATTR-CM

Educational resourcesExpert VideosDownloadable ResourcesOn Demand CongressesSupport & ResourcesVideosMaterials

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Current standard of care and emerging treatment strategies

Current standard of care treatment options available for ATTR-CM are aimed at symptom management, supportive care including pain management, nutritional and mobility support and mitigation of the effects of the disease on other organs.1

In February 2020, marketing authorisation in the United Kingdom was granted for Vyndaqel▼ (tafamidis), a transthyretin stabiliser, available as a once-daily 61 mg oral capsule2, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Whilst there is a licence for Vyndaqel for ATTR-CM in the UK, there is not currently funded NHS access.

Additional treatment options are currently under investigation. Emerging treatment strategies are aimed at reducing the formation of the amyloid fibrils by targeting different stages of their development.3

Note: Some of these are investigational approaches, and no conclusions can be made about safety and efficacy. 

Explore more

See other educational resources available

 Explore more Loading

References:

Hawkins PN, Ando Y, Dispenzen A et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015; 47: 625–638.Vyndaqel Summary of Product Characteristics for GB available at www.medicines.org.uk/emc and Vyndaqel Summary of Product Characteristics for NI available at www.emcmedicines.com/en-GB/northernireland/Ruberg FL, Grogan M, Hanna M et al. Transthyretin Amyloid Cardiomyopathy. JACC State-of-the-Art Review. JACC. 2019; 73(22): 2872–2891.Maurer MS, Elliott P, Comenzo R et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017; 135(14): 1357–1377.Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018; 33(5): 571–579.Judge DP, Heitner SB, Falk RH et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019; 74(3): 285–295.
PP-VYN-GBR-1012. November 2022
Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.​​​​​​​

Sign up nowLoading

​​​​​​PP-PFE-GBR-2809. October 2020

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​